New drug naderin may help patients fight infections during cancer and TB therapy
NCT ID NCT07671508
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. Results showed that Naderin shortened the duration of low white blood cell counts by 4-5 days and reduced the number of infections, suggesting it may help patients better tolerate aggressive treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Naderin (sodium nucleinate)
What this could lead to
If it works, this could provide a supportive treatment to help patients better tolerate chemotherapy and other aggressive therapies by reducing infections and blood cell count drops.
What could go wrong
This is a small, completed Phase 2/3 trial with only 75 participants. Results may not apply to all patients, and the drug's safety and effectiveness need confirmation in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS (TB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.